Tirzepatide
FDA-Approved moleculeCompounded form not FDA-approvedDual GIP/GLP-1 receptor agonist
Medical emergency? If you have a medical emergency, call 911 or go to the nearest emergency room. Do not wait.
- How it works (plain English)
- Activates two gut-hormone receptors (GIP and GLP-1) involved in appetite regulation and blood-sugar control, which together can reduce appetite and food intake.
- Key risks
- Commonly reported: nausea, diarrhea, decreased appetite, vomiting, constipation. Boxed warning for thyroid C-cell tumors based on rodent studies; pancreatitis reported.
- Who should not use it
- Personal or family history of medullary thyroid carcinoma or MEN 2; known hypersensitivity.
- Drug interactions
- May reduce effectiveness of oral contraceptives; additive hypoglycemia risk with insulin or insulin secretagogues.
Compounded medications are prepared by licensed US pharmacies on a valid prescription and are not reviewed or approved by the FDA for safety or effectiveness. Treatment is provided only when prescribed by a licensed provider.
This page is general educational information, not medical advice, and is not a complete list of risks. Your prescribing provider will review your full history. Report side effects to your provider; you may also report to the FDA at 1-800-FDA-1088.